Koca Rafet, Altinyazar H Cevdet, Eştürk Emel
Department of Dermatology, Faculty of Medicine, Zonguldak Karaelmas University, Zonguldak, Turkey.
Int J Dermatol. 2003 Aug;42(8):632-5. doi: 10.1046/j.1365-4362.2003.01981.x.
Seborrheic dermatitis is a common, chronic, papulosquamous dermatosis. Although several types of treatment have been developed, repetitive treatment courses are often necessary.
To perform a randomized, placebo-controlled, double-blind clinical study with metronidazole 0.75% gel in patients with mild to moderate seborrheic dermatitis of the face.
Eighty-four patients (52 males and 32 females) with seborrheic dermatitis were enrolled in the study. Patients were randomly allocated to the application of metronidazole 0.75% gel or placebo to their facial lesions, twice daily for 8 weeks. Patients were scored with regard to the severity of the lesions at the initial evaluation and every 2 weeks for 2 months. All patients were evaluated for a final assessment of improvement at the end of the study.
At baseline, both treatment groups were comparable in terms of demographic data and lesion severity score. Seventy-eight patients (48 males and 30 females), 48 (62%) in the metronidazole group and 30 (38%) in the placebo group, completed the study. Two patients in the metronidazole group and four patients in the placebo group left the study. There was no statistically significant difference in the change in the mean severity score between the two groups at the end of the study (P > 0.05). At the final evaluation of the response at 8 weeks, no statistically significant difference was found between the treatment groups (P > 0.05). Metronidazole gel was generally tolerated well during the study.
Metronidazole 0.75% gel and placebo show similar efficacy in the treatment of seborrheic dermatitis.
脂溢性皮炎是一种常见的慢性丘疹鳞屑性皮肤病。尽管已经开发了几种治疗方法，但通常需要重复治疗疗程。
对0.75%甲硝唑凝胶治疗轻至中度面部脂溢性皮炎患者进行一项随机、安慰剂对照、双盲临床研究。
84例脂溢性皮炎患者（52例男性和32例女性）纳入研究。患者被随机分配在面部皮损处涂抹0.75%甲硝唑凝胶或安慰剂，每日两次，共8周。在初始评估时以及之后的2个月内每2周对患者的皮损严重程度进行评分。在研究结束时对所有患者进行改善情况的最终评估。
在基线时，两个治疗组在人口统计学数据和皮损严重程度评分方面具有可比性。78例患者（48例男性和30例女性）完成了研究，其中甲硝唑组48例（62%），安慰剂组30例（38%）。甲硝唑组有2例患者、安慰剂组有4例患者退出研究。研究结束时两组之间的平均严重程度评分变化无统计学显著差异（P>0.05）。在8周时对反应的最终评估中，治疗组之间未发现统计学显著差异（P>0.05）。在研究期间，甲硝唑凝胶总体耐受性良好。
0.75%甲硝唑凝胶和安慰剂在治疗脂溢性皮炎方面显示出相似的疗效。
